US 12,435,337 B2Granted

Inhibitors of expression and/or function

AssigneeE-Therapeutics PLC

InventorsAlan Victor Whitmore, Julie Borgel, Amy McCarthy, Graham Craggs, James Longden, Ines De Santiago, Duncan Brown, Ahmad Ali Mortazavi, Viviana Mannella, Muthusamy Jayaraman, Alexandre Debacker, Adrian Mogg

Life of this patent

Estimating the term…

Abstract

The present invention relates to inhibitors, and compositions containing inhibitors, and uses of the same in the treatment or prevention of diabetes.

Claims19

Dependent claims

A method for treating diabetes in an individual, comprising administering to the individual an inhibitor of expression of B4GALT1, wherein the inhibitor is an siRNA oligomer.

Dependencies are inferred from the claim text.

Facts

Application: 18/640,905Filed 19 Apr 2024 · continuation
Priority: GB 22081241 Jun 2022
Published: US 2024/0336922 A110 Oct 2024
Granted: 7 Oct 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

C12N 15/1137
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming…: against enzymes
C12Y 204/01022
Hexosyltransferases: lactose synthase
C12Y 204/01038
Hexosyltransferases: beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase
C12Y 204/0109
Hexosyltransferases: n-Acetyllactosamine synthase

Family

Application63/369,627Us provisional application · filed 27 Jul 2022
PCT/EP2023/064762Parent of this continuation · filed 1 Jun 2023
US 2024/0336922 A1Pre-grant publication · published 10 Oct 2024
US 12,435,337 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results